SPARC — Sun Pharma Advanced Research Co Share Price
0.000.00%
Last trade - 00:00- IN₹48.86bn
- IN₹49.77bn
- IN₹755.45m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 2.7 | ||
| PEG Ratio (f) | 0.21 | ||
| EPS Growth (f) | 14.58% | ||
| Dividend Yield (f) | 11.15% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 79.5 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -928.27% | ||
| Return on Equity | -305.57% | ||
| Operating Margin | -635.14% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 768.14 | 2,529.57 | 1,372.49 | 2,387.8 | 755.45 | 545,334 | 605,158 | -16.21% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +14.58 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sun Pharma Advanced Research Company Limited is an India-based clinical-stage biopharmaceutical company that focuses on developing therapeutics to improve standards of care for patients worldwide. The Company’s therapeutic focus is in the area of oncology, neurology and immunology. Its lead oncology programs include vodobatinib (SCO-088), a BCR-ABL targeting tyrosine kinase inhibitor for refractory chronic myelogenous leukemia, and an anti-MUC-1 antibody-drug conjugate (ADC) with the potential to treat multiple cancers. Its lead therapeutic agent, vodobatinib (SCC-138), is a c-ABL inhibitor that has the potential to be a therapy modulating cellular homeostasis in neurodegenerative diseases. Vibozilimod (SCD-044) is a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist targeting autoimmune disorders. SCD-153 is a topical agent being developed for the treatment of alopecia areata. SBO-154 is an ADC being developed for multiple tumor types expressing MUC-1.
Directors
- Dilip Shanghvi NEC (65)
- Anil Raghavan CEO
- Chetan Rajpara CFO
- Dinesh Lahoti CCO
- T. Rajamannar NED
- Sudhir Valia NED (64)
- Ferzaan Engineer IND
- S. Mohanchand Dadha NID
- Bhavna Doshi NID
- Goverdhan Mehta NID (77)
- Andrea Vasella NID
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 1st, 2006
- Public Since
- July 18th, 2007
- No. of Shareholders
- 104,868
- No. of Employees
- 409
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 324,521,588
- Address
- 17B Mahal Industrial Estate, MUMBAI, 400093
- Web
- https://www.sparc.life/
- Phone
- +91 2266455645
- Contact
- Jaydeep Issrani
- Auditors
- S R B C & CO LLP
Upcoming Events for SPARC
Q1 2026 Sun Pharma Advanced Research Co Ltd Earnings Release
Sun Pharma Advanced Research Co Ltd Annual Shareholders Meeting
Similar to SPARC
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Sun Pharma Advanced Research Co share price?
As of Today at 23:30 UTC, shares in Sun Pharma Advanced Research Co are trading at IN₹149.77. This share price information is delayed by 15 minutes.
How has the Sun Pharma Advanced Research Co share price performed this year?
Shares in Sun Pharma Advanced Research Co last closed at IN₹149.77 and the price had moved by -44.71% over the past 365 days. In terms of relative price strength the Sun Pharma Advanced Research Co share price has underperformed the S&P BSE 100 Index by -47.92% over the past year.
What are the analyst and broker recommendations for Sun Pharma Advanced Research Co?
The overall consensus recommendation for Sun Pharma Advanced Research Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Sun Pharma Advanced Research Co dividend yield?
Sun Pharma Advanced Research Co does not currently pay a dividend.
Does Sun Pharma Advanced Research Co pay a dividend?
Sun Pharma Advanced Research Co does not currently pay a dividend.
When does Sun Pharma Advanced Research Co next pay dividends?
Sun Pharma Advanced Research Co does not currently pay a dividend.
How do I buy Sun Pharma Advanced Research Co shares?
To buy shares in Sun Pharma Advanced Research Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sun Pharma Advanced Research Co?
As of the previous close price of IN₹149.77, shares in Sun Pharma Advanced Research Co had a market capitalisation of IN₹48.86bn.
Where are Sun Pharma Advanced Research Co shares listed?
Here are the trading details for Sun Pharma Advanced Research Co:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: SPARC
What kind of share is Sun Pharma Advanced Research Co?
Based on an overall assessment of its quality, value and momentum Sun Pharma Advanced Research Co is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sun Pharma Advanced Research Co share price forecast for 2025?
The analyst consensus target price for shares in Sun Pharma Advanced Research Co is IN₹1,362.81. That is 809.94% above the last closing price of IN₹149.77.
Analysts covering Sun Pharma Advanced Research Co currently have a consensus Earnings Per Share (EPS) forecast of IN₹48.35 for the next financial year.
Find out moreWhat is the trend in the Sun Pharma Advanced Research Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sun Pharma Advanced Research Co. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -25.57%.
As of the last closing price of IN₹149.77, shares in Sun Pharma Advanced Research Co were trading -21.9% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sun Pharma Advanced Research Co PE Ratio?
The Sun Pharma Advanced Research Co PE ratio based on its reported earnings over the past 12 months is 2.7. The shares last closed at IN₹149.77.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sun Pharma Advanced Research Co?
Sun Pharma Advanced Research Co's management team is headed by:
- Dilip Shanghvi - NEC
- Anil Raghavan - CEO
- Chetan Rajpara - CFO
- Dinesh Lahoti - CCO
- T. Rajamannar - NED
- Sudhir Valia - NED
- Ferzaan Engineer - IND
- S. Mohanchand Dadha - NID
- Bhavna Doshi - NID
- Goverdhan Mehta - NID
- Andrea Vasella - NID